Medindia
Advertisement

Fibromyalgia Treatment Market Value Heading for $1.9 Billion by 2023 in Seven Major Markets

by Shirley Johanna on May 14, 2015 at 5:23 PM

Fibromyalgia Treatment Market Value Heading for $1.9 Billion by 2023 in Seven Major Markets
The fibromyalgia treatment market value across seven major markets (7MM) of the US, France, Germany, Italy, Spain, the UK, and Japan, will rise from $1.8 billion in 2013 at a low Compound Annual Growth Rate (CAGR) of 0.72% to reach $1.9 billion by 2023, according to research and consulting firm GlobalData.

PharmaPoint's latest report 'Global Drug Forecast and Market Analysis to 2023' states that while this growth will be primarily driven by the potential introduction of four late-stage pipeline agents, consisting of reformulations of existing therapies and "me-too" products, it will also be dampened by the simultaneous patent expiries of the key branded products on the market.
Advertisement

Maura Musciacco, GlobalData's Director of Neurology and Ophthalmology, says the US will consolidate its position as the dominant market, with the country's share increasing from 83% of fibromyalgia treatment sales in 2013 to 86% by 2023.

Musciacco explains: "The US is the only country among the 7MM with three approved brands: Lyrica, Cymbalta, and Savella. Along with its higher drug prices and prescribing rates, the largest fibromyalgia population, and a greater number of pipeline products compared with the other six countries, the US holds a greater share of the fibromyalgia treatment arena."
Advertisement

"The small range of currently available fibromyalgia therapeutics means that the market will welcome new products that can offer patients better efficacy, convenience, and safety. To date, four pipeline agents will potentially be introduced by 2023, mainly in the US."

These products include two reformulations, namely Pfizer's Lyrica CR and Tonix Pharmaceutical's TNX-102 SL, and two "me-too" products, namely Daiichi Sankyo's DS-5655 and Theravance Biopharma's TD-9855.

Musciacco continues: "The estimated cost of these treatments will be comparatively higher than the currently available fibromyalgia therapies and the inexpensive generic products. These higher costs will drive an increase in the overall value of the fibromyalgia market over the forecast period."

"However, Lyrica, Cymbalta, and Savella have already or will experience generic erosion between 2013 and 2023. Generic medicines are likely to dominate sales in countries where the pipeline products are limited or not available, while markets crowded with generics will see limited sales growth for new entrants."

Source: Medindia
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Category
What's New on Medindia
Lower Respiratory Tract Infections Linked to Obstructive Sleep Apnea in Children
Type 2 Diabetes can be Controlled by Unripen Green Jackfruit Flour
Covid Pandemic: How Parents can Help Kids Deal with Back-to-School Anxiety
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Chest Pain Fibromyalgia Hypermobility Syndrome Costochondritis Myofascial Pain Syndrome 

Recommended Reading
Fibromyalgia
Fibromyalgia (FM) is a chronic health condition charecterized by widespread pain and stiffness in .....
Research Sheds Light on Fibromyalgia and the Role of Brain Connectivity in Pain Inhibition
Despite extensive research, the cause of fibromyalgia, a chronic pain syndrome is not known....
Clinic Study Shows Young People Report Worse Fibromyalgia Than Older Patients
A Mayo Clinic study shows that young and middle-aged fibromyalgia patients report worse symptoms ......
Fibromyalgia Patients can Get Some Relief Through Whole-Body Vibration Exercise
People suffering from fibromyalgia can benefit by whole-body vibration exercise, which can reduce .....
Chest Pain
Ask any one who has experienced intense chest pain and they will vouch for the fact that it was the ...
Costochondritis
Inflammation of the cartilage that joins the ribs to the breastbone is known as Costochondritis. It ...
Hypermobility Syndrome
Hypermobility Syndrome is a condition in which a person can move his joints far beyond the normal .....
Myofascial Pain Syndrome
A patient with myofascial syndrome suffers from pain at trigger points, which is referred to other ....

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use